Chotiyarnwong P, McCloskey E, Eastell R, et al. - In view of the observed association of treatment with a lower incidence of non-fracture-related falls in the pivotal placebo-controlled fracture trial of the RANKL inhibitor denosumab in women with postmenopausal osteoporosis, researchers conducted this ad hoc exploratory analysis compiling data from five placebo-controlled trials of denosumab in order to determine consistency across trials, if any, of the reduction of fall incidence. In this analysis, they included trials in women with postmenopausal osteoporosis and low bone mass, men with osteoporosis, women receiving adjuvant aromatase inhibitors for breast cancer, and men receiving androgen deprivation therapy for prostate cancer. Assessment of 10,036 individuals was done in this analysis; of these, 5,030 received denosumab 60 mg subcutaneously once every 6 months for 12–36 months and 5,006 received placebo. As per outcomes, denosumab may result in a decrease in the risk of falls in addition to its demonstrated fracture risk reduction by decreasing bone resorption and improving bone mass.